Disease · EFO_0004285
Comparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 17 of 17
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Linagliptin 5 mg vs Placebo: serious adverse events | 17 of 182 | 8 of 178 | 360 | NCT01792518 | Trial comparisons |
| AZD1722 vs Placebo: deaths from any cause | 0 of 77 | 0 of 77 | 154 | NCT01847092 | Trial comparisons |
| AZD1722 vs Placebo: serious adverse events | 3 of 77 | 2 of 77 | 154 | NCT01847092 | Trial comparisons |
| GKT137831 vs Placebo: deaths from any cause | 0 of 68 | 0 of 68 | 136 | NCT02010242 | Trial comparisons |
| GKT137831 vs Placebo: serious adverse events | 3 of 68 | 5 of 68 | 136 | NCT02010242 | Trial comparisons |
| Hydroxycarbamide vs Placebo: deaths from any cause | 0 of 46 | 2 of 40 | 86 | NCT03806452 | Trial comparisons |
| Hydroxycarbamide vs Placebo: serious adverse events | 5 of 46 | 7 of 40 | 86 | NCT03806452 | Trial comparisons |
| Hydroxycarbamide vs Placebo: Proportion of Patients With a Shift From Microalbuminuria to Macroalbuminuria | 3 of 43 | 3 of 38 | 81 | NCT03806452 | Trial comparisons |
| Hydroxycarbamide vs Placebo: Proportion of Patients With a Shift From Macroalbuminuria to Microalbuminuria | 1 of 43 | 2 of 38 | 81 | NCT03806452 | Trial comparisons |
| Hydroxycarbamide vs Placebo: Number of Patients Achieving at Least a 30% Decrease in ACR Baseline Value | 18 of 43 | 15 of 38 | 81 | NCT03806452 | Trial comparisons |
| Hydroxycarbamide vs Placebo: Proportion of Patients With a Shift From Macroalbuminuria to Normoalbuminuria | 1 of 43 | 0 of 38 | 81 | NCT03806452 | Trial comparisons |
| Verinurad 9 mg+Febuxostat 80 mg vs Placebo: deaths from any cause | 0 of 32 | 0 of 28 | 60 | NCT03118739 | Trial comparisons |
| Verinurad 9 mg+Febuxostat 80 mg vs Placebo: serious adverse events | 5 of 32 | 3 of 28 | 60 | NCT03118739 | Trial comparisons |
| Hydroxycarbamide vs Placebo: Proportion of Patients With a Shift From Microalbuminuria to Normoalbuminuria | 10 of 43 | 7 of 8 | 51 | NCT03806452 | Trial comparisons |
| Atorvastatin vs Placebo: deaths from any cause | 0 of 13 | 0 of 13 | 26 | NCT01732718 | Trial comparisons |
| Atorvastatin vs Placebo: serious adverse events | 1 of 13 | 3 of 13 | 26 | NCT01732718 | Trial comparisons |
| PF-03882845 3 mg vs Placebo: serious adverse events | 0 of 5 | 0 of 4 | 9 | NCT01488877 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0004285/comparisons